Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients

Table 2 Distribution of demographic and clinical characteristics in group II

Demographic and clinical features	n	Frequency of CIK cells immunotherapy, n (%)				χ2	P
		0	1-10	11-25	> 25
Sex
Men	122	62 (76.5)	39 (84.8)	13 (86.7)	8 (57.1)	5.573	0.134
Women	34	19 (23.5)	7 (15.2)	2 (13.3)	6 (42.9)
Age (yr)
≤ 45	14	7 (8.6)	5 (10.9)	1 (6.6)	1 (7.1)	1.153	0.979
45 < age ≤ 60	71	36 (44.4)	20 (43.5)	7 (46.7)	8 (57.1)
> 60	71	38 (47.0)	21 (45.6)	7 (46.7)	5 (35.8)
Tumor sitea
Gastric cardia
Yes	58	30 (37.0)	17 (37.0)	5 (33.3)	6 (42.9)	0.290	0.962
No	98	51 (63.0)	29 (63.0)	10 (66.7)	8 (57.1)
Gastric body
Yes	64	35 (43.2)	19 (41.3)	5 (33.3)	5 (35.7)	0.691	0.875
No	92	46 (56.8)	27 (58.7)	10 (66.7)	9 (64.3)
Gastric antrum
Yes	36	17 (21.0)	10 (21.7)	4 (26.7)	5 (35.7)	1.614	0.656
No	120	64 (79.0)	36 (78.3)	11 (73.3)	9 (64.3)
Tumor sizec (cm)
< 5	76	43 (59.7)	17 (45.9)	7 (58.3)	9 (81.8)	4.834	0.184
≥ 5	56	29 (40.3)	20 (54.1)	5 (41.7)	2 (18.2)
Histological typec
Differentiated	52	28 (35.4)	12 (30.0)	6 (40.0)	6 (50.0)	1.760	0.624
Poorly-differentiated	94	51 (64.6)	28 (70.0)	9 (60.0)	6 (50.0)
Invasionc
Yes	112	55 (76.4)	38 (90.5)	10 (90.9)	9 (81.8)	4.226	0.238
No	24	17 (23.6)	4 (9.5)	1 (9.1)	2 (18.2)
Lymph node metastasisc
Yes	100	55 (76.4)	31 (75.6)	7 (58.3)	7 (63.6)	2.371	0.499
No	36	17 (23.6)	10 (24.4)	5 (41.7)	4 (36.4)
Relapse
Yes	98	58 (71.6)	31 (67.4)	8 (53.3)	1 (7.1)	15.633	0.0004
No	58	23 (28.4)	15 (32.6)	7 (46.7)	13 (92.9)
Pathological grade
1	2	1 (1.2)	1 (2.2)	0 (0.0)	0 (0.0)	2.976b	0.3953
2	27	18 (22.2)	8 (17.4)	0 (0.0)	1 (7.1)
3	92	44 (54.3)	25 (54.4)	12 (80.0)	11 (78.6)
4	35	18 (22.2)	12 (26.0)	3 (20.0)	2 (14.3)
Tumor stage
I	14	9 (11.1)	3 (6.5)	0 (0.0)	2 (14.2)	13.66b	0.0386
II	22	23 (28.4)	3 (6.5)	1 (6.7)	6 (42.9)
III	102	38 (46.9)	34 (73.9)	13 (86.7)	6 (42.9)
IV	18	11 (13.6)	6 (13.1)	1 (6.6)	0 (0.0)

^aTumor sites in some cases were repeated;

^bBecause the theoretical value is less than 1, χ² was performed for patients who received cytokine-induced killer (CIK) cells immunotherapy at the frequencies of 11-25 and > 25, and for those who underwent CIK cells immunotherapy at the frequencies of 1-10, 11-25 and > 25;

^cMissed cases.